# Team MedVerse: final-submission audit and validation plan

**Review date:** 2 November 2026. **Status:** static document/code audit and proposed validation plan; not a new experimental PASS.

## 1. Evidence reviewed

The latest document was `Team_MedVerse_Initial_Design_Overview_Corpus_Aligned[Aliyu Ibrahim].docx`. The implementation examined was the uploaded `MedVerse-Agent-Cumulative-Gate26(1).zip`, alongside the uploaded SAMAAM repository. The latest document rendered to eight pages in the review environment. Pagination may vary across Word environments, but the exported final submission must be verified against the five-page limit.

Numerical results were deliberately omitted from the initial mentor submission. This is not treated as a defect. The final submission should distinguish completed reference-benchmark measurements, newly measured integration evidence, and proposed capabilities.

This audit inspected source code, structured records, and saved outputs. It did not rerun the complete application, reproduce model training, certify Korean legal interpretations, or independently validate clinical deployment.

## 2. Findings and required actions

### A01 — Evidence identity and version reconciliation

The uploaded archive's benchmark SHA-256 is `3936884644117f793895c2865e4bfb319a5a2eeed1dbb5bda63324ec8a44ac1b`. It matches the archived Gate 26A status. The earlier console transcript supplied in the conversation reports `b5b8be75acaf144dc372a117347359f07ac790b4ac4f4494c090bec683d83f6f`. These are distinct byte-level artifacts. This audit does not establish whether the difference is semantic or formatting-related.

Select one release/run as the final evidence reference. Preserve both historical records, identify their provenance, and do not combine latency figures or freeze claims across runs. The stored Gate 26B status reports PASS 9/9 and Gate 26A reports PASS 8/8; these are archived results, not a fresh execution by this audit.

### A02 — Corpus inventory is useful, but counts are not completeness

`data/policy/candidate_v0.4/policy_records_v0.4_candidate.json` contains 44 records, 42 marked retrieval-eligible, and 13 document identifiers. These identifiers must not automatically be described as 13 independent legal documents; the naming registry requires normalization. Metadata includes 21 `verified_article_record` entries, 21 `full_official_document_obtained` entries and two excluded press-release entries.

For final release, publish a source inventory separately from the chunk/record inventory. Distinguish official-source availability, exact clause transcription, translation review, interpretation review and executable-rule approval. An internal verification label alone is not independent legal validation.

### A03 — The retrieval prefilter does not itself implement temporal applicability

`medverse/knowledge_base/jurisdictional_semantic_kb.py`, lines 90–97, filters `retrieval_eligible`, jurisdiction, and agent access. The inspected function does not compare effective dates with the scenario date or determine substantive legal applicability. If another component supplies these controls, expose that component and its test evidence; otherwise narrow the claim or add a versioned applicability layer.

Keep the established eligibility → jurisdiction → agent access → semantic ranking sequence. Do not turn semantic similarity into legal authorization. Distinguish role-scoped retrieval of public legal sources from authorization to see patient-level evidence.

### A04 — Source version and source text need release-level checking

The PIPA Article 28-2 to 28-5 records carry effective date 2026-09-11, but their linked official page returned a 2025-10-02 version during this review. Reconcile the stored clause, effective date, official locator and hash; the observation establishes a version mismatch, not that every clause interpretation is substantively wrong.

Sampled statute records store English paraphrases and Korean descriptors with `full_text_stored=false`. Do not present this as a fully transcribed authoritative Korean clause corpus. Add exact evidence spans and locators for the rules used by the flagship scenario.

The legal mapping should also narrow Bioethics Article 37 to its human-derived-material scope and DMP Enforcement Rule Article 14 to its clinical-trial-plan scope, subject to domain/legal review. Do not apply a specialized provision indiscriminately to all monitoring data or all digital medical software.

### A05 — Integration currently selects a fixture action for validation

In `medverse/integration/gate19_grounded_pipeline.py`, lines 113–125, an assessment is generated, but the action passed to the boundary validator is `case["boundary_action"][agent_id]`. The trace separately records recommended actions and the fixture-selected action. This is legitimate deterministic integration testing; it is not proof that the agent's actual proposal drives the execution boundary.

Add a new, separately versioned adapter that validates the actual proposal and preserves a proposal ID through harmonization and final action commitment. Any coordinator-synthesized alternative must be validated again before a modeled side effect occurs. Preserve the existing Gate 19 and Gate 26 fixtures and results.

### A06 — Progressive release needs explicit runtime evidence

The inspected Gate 19 path loads all DT updates before producing the case result. The inspected Streamlit path in `demo/competition_app.py`, lines 78–83, caches a full `run_case` output. This observation applies to that path and does not prove that no progressive module exists elsewhere.

The final demo needs an event cursor, role-specific observations at each step, independent timestamps, and tests that future events cannot influence earlier decisions. A visual replay of a fully computed scenario is not equivalent to an agent processing incomplete, progressively released information.

### A07 — Gate 26 is an architectural reference ablation

The benchmark supplies structured institutional positions and flags, including policy/mandate validity and evidence sufficiency. It evaluates seven semantic archetypes with ten contextual variants each. It does not directly evaluate the complete live legal-retrieval pipeline, free-text clinical reasoning, or arbitrary real-world institutions.

Preserve the existing B1–B5 results and their finite, scenario-based claim boundary. Do not pool repeated contexts as independent clinical cases or infer zero real-world risk from zero recorded benchmark violations.

### A08 — Baseline and metric descriptions must match the code

In the Gate 26 comparison runner, B3 is a majority-intent voting reference implementation with tie escalation, not a multi-round LLM debate. B1 emits actions under `omniscient_agent`; the scorer classifies that ownership as an authority violation. These are frozen design choices, not general proofs that every centralized agent or debate system is unsafe.

Institutional correctness counts included required actions and excluded forbidden actions. Coordination quality is the average of state-label correctness, action-set F1, communication/evidence-request-set F1 and escalation correctness. Exact workflow match compares sets and state/escalation, not execution order. Different native state vocabularies also affect the score. Provide these definitions in the repository and use a behavior-based oracle for the new integrated evaluation.

### A09 — Selected actions are not a temporal execution trace

`_output` in the Gate 26 runner stores `executed_actions` as `sorted(set(actions))`. Unsafe execution checks membership in the frozen allowed-action set. This is useful action-admissibility evidence, but it does not establish precondition ordering, human approval before release, consent-change handling between proposal and execution, or real API enforcement.

The new scenario evaluation should measure approved, rejected, pending and committed actions separately, with action IDs, institution ownership, validation timestamps, policy versions and simulated side effects. Measure actual end-to-end latency separately from the old microsecond coordinator benchmark.

### A10 — Report restructuring, not simple shrinking

The initial document repeats role/source mapping across Tables 3 and 5. Move the full clause inventory and detailed processing steps to the repository/technical annex. Keep one compact role-obligation table, one architecture figure, one progressive trace and a compact evidence panel in the five-page report. Retain the current introduction and the medical-metaverse framing, while distinguishing proposed XR/clinical interfaces from implemented governance functions.

## 3. Proposed bounded final-validation suite

These are proposed experiments, not executed results. Use separate release directories and identifiers, not overwritten Gate 26 files. Numerical sample counts below are planning choices and must be frozen before execution.

### FINAL-KB-01 — Korean source and retrieval assurance

1. **Question:** Does each role receive the correct, current, source-verifiable evidence without unauthorized evidence inclusion?
2. **Frozen assumptions:** KR deployment; selected oncology workflow; source hierarchy; eligibility/jurisdiction/access-before-ranking; reviewed source inventory.
3. **Changed component:** A versioned corpus/evidence-normalization and applicability layer; no modification of historical learned models or benchmark outputs.
4. **Dataset and provenance:** Forty independently specified query-intent families, eight per role, each expressed in Korean and English: 80 query records. Query and required-clause labels come from reviewed obligations, not embedding neighbors.
5. **Split:** Twenty intent families for development and twenty sealed for confirmation, stratified by role. Both language forms of a family remain together. All official source documents remain available in the fixed KB; the holdout is over queries, not a claim of unseen-law generalization.
6. **Leakage audit:** Group by underlying question, template and paraphrase family. Prevent tuning on held-out answers. Include fixed negative tests for wrong jurisdiction, obsolete version, missing applicability evidence and inappropriate role-specific patient evidence.
7. **Oracle:** Independently specified required/acceptable provisions, source version, applicability conditions, source authority and permitted evidence view. Record unresolved interpretation as uncertainty, not automatic permission.
8. **Metrics:** Recall@3 with a stated denominator; all-required-provisions coverage where several clauses are needed; citation/version fidelity; Korean–English answer consistency; inappropriate retrieval; unsupported authorization; correct abstention.
9. **Pass/fail:** Freeze exact safety assertions before running. Every release-critical source must have a verified locator/version; no forbidden evidence inclusion or unsupported permission in the finite hard-boundary suite. Retrieval-quality results are reported separately, not made perfect by changing thresholds after failure.
10. **Raw outputs:** Source manifest, query family ID, language, candidate filters, ranked IDs/scores, cited text/locator, eligibility decisions and expected outcome.
11. **Interpretation:** Separately assess retrieval quality, legal applicability and execution permission. One cannot substitute for another.
12. **Claim boundary:** The reviewed sources and tested query families, not comprehensive Korean healthcare law.
13. **Next dependency:** Freeze the release corpus and rule interpretation used by FINAL-WF-01.

### FINAL-WF-01 — Progressive clinical coordination and action lineage

1. **Question:** Does harmonization preserve a legitimate care pathway while preventing unauthorized research disclosure as evidence and authorization change?
2. **Frozen assumptions:** Modeled oncology DT workflow, no diagnosis/prescription autonomy, five distinct mandates, fixed reviewed policies, role-scoped views and explicit human authority.
3. **Changed component:** The runtime adapter/event sequencing/validation-to-execution integration, after development. Preserve old gates. No model retuning during confirmation.
4. **Dataset and provenance:** Twelve independently specified workflow families with four to six progressively released events each; derive obligations from the reviewed corpus and clinician-informed workflow rather than copying the B5 code.
5. **Split:** Four development families and eight fresh confirmation families. Variants and event-order changes from one family stay together. Later events remain inaccessible until their release.
6. **Leakage audit:** Separate oracle and baseline implementations; hide future events; prevent policy answers or expected coordination states being injected into agent inputs. Do not count event steps as independent patients.
7. **Oracle:** Accepted outcome predicates, prohibited transitions, evidence prerequisites and permitted alternative workflows. Exact state names are secondary; multiple compliant workflows may be accepted.
8. **Metrics:** Authorized task completion, unauthorized committed actions, wrong-owner actions, premature release, future-information exposure, unnecessary escalation, appropriate escalation, disclosure minimization and end-to-end p50/p95 latency.
9. **Pass/fail:** Freeze zero-violation assertions for the finite hard-boundary tests and positive obligations for legitimate care. A deny-all system cannot pass utility requirements. B5 beating B4 is a hypothesis, never an integrity-pass condition.
10. **Raw outputs:** Event cursor, role observation snapshot, query/response provenance, proposal ID, validator decision, owner, dependency status, human approval, coordinator output, final revalidation and modeled side effect.
11. **Interpretation:** Compare the same independent per-role filtering and harmonization configurations with shared local assessments/validators. A deny-all control diagnoses availability-by-abstention. Do not silently replace the old B4/B5 results with the new ones.
12. **Claim boundary:** Scenario-based institutional coordination and simulated side effects; no clinical deployment or legal certification.
13. **Next dependency:** Release-candidate package and independent replay in FINAL-REL-01.

### FINAL-REL-01 — Reproducibility, auditability and submission conformance

1. **Question:** Can an independent reviewer reproduce the advertised behavior and inspect every consequential decision?
2. **Frozen assumptions:** One release identifier with pinned source corpus, rules, models, configurations and benchmark/output hashes.
3. **Changed component:** Packaging and operational documentation only; any functional change requires a new release identifier and appropriate reconfirmation.
4. **Dataset and provenance:** Frozen demo/confirmation cases and a predetermined fault checklist covering unavailable evidence, invalid approval, source failure, unexpected agent output and event replay.
5. **Split:** New evaluator/environment, with confirmation cases not used for implementation tuning. This is a reproduction check, not a new clinical sample.
6. **Leakage audit:** No oracle labels in runtime input; no private data, credentials or embargoed institution-specific SOPs in the public export.
7. **Oracle:** Frozen scenario obligations, reproducibility checklist and official submission requirements.
8. **Metrics:** Successful installation/replay, complete trace fields, artifact hash consistency, fault-response correctness, task completion and report/page/link compliance.
9. **Pass/fail:** A clean installation can run advertised commands; required artifacts and evidence references resolve; no unsafe fallback authorizes actions after missing evidence; final PDF meets the page limit. Report limitations openly.
10. **Raw outputs:** Environment/dependency record, command transcript, validation results, logs, file hashes, exported report and reviewer issue record.
11. **Interpretation:** Distinguish environmental/dependency failure from representation, oracle, coverage or model failure.
12. **Claim boundary:** Reproducibility on the documented tested environment, not production reliability assurance.
13. **Next dependency:** Final submission and a clearly identified demo release; no unrecorded post-freeze changes.

## 4. Scope controls

Do not reopen historical Privacy, Cyber, S1–S4 or Gate 26 thresholds. Do not introduce full XR, a new fine-tuning project, or a journal-scale adversarial framework merely to appear more sophisticated. Add only changes necessary to make the declared source-to-action chain observable and testable.

A public-law retrieval partition is a role-design choice. Protection of patient observations, tool credentials, disclosures and execution authority requires separate controls and separate tests. Keep international comparison sources explicitly non-binding for Korean execution; they can inform gap analysis without becoming substitute Korean authorization.

No numerical superiority is guaranteed by this plan. No first-prize outcome can be guaranteed. The objective is a traceable, defensible and independently inspectable final submission.

## 5. Audited artifact fingerprints

Paths below are relative to the root of the uploaded MedVerse-Agent cumulative archive.

| Artifact | SHA-256 |
|---|---|
| `medverse/knowledge_base/jurisdictional_semantic_kb.py` | `f4310e844e9d2126214969d21126019db28b20c1f5067f59fcbc047e93fb44d8` |
| `medverse/integration/gate19_grounded_pipeline.py` | `ab17e58e0911059afbc836cb22e63f167dabd85902c7e4cb3a91e4bd083b4136` |
| `medverse/gates/gate26b_architectural_baseline_comparison.py` | `346c7536e63971508f815238766ae3090964b54ba2baeb904aaf03cb1d1f3db7` |
| `medverse/evaluation/gate26_baseline_benchmark.py` | `ad563e150d959f17db0bb849c9611a95d527e9fc9064f18358ff1bb949a79ce8` |
| `demo/competition_app.py` | `0d3aa416df07e4080acbb280a59f1f08a43ea9f68ea3aaaa0934585000b5565a` |
| `data/policy/candidate_v0.4/policy_records_v0.4_candidate.json` | `c4e6930d8585f787e7492ef5fe630d52368436e276f8aabd140d4d81767a024d` |
| `data/evaluation/gate26/gate26_architectural_baseline_cases.json` | `3936884644117f793895c2865e4bfb319a5a2eeed1dbb5bda63324ec8a44ac1b` |
| `outputs/gate26/gate26_baseline_summary.csv` | `e0e2697ef1817becf5456c6ba130a3f35f55a62bac338f9e447c6ac1f89b0ca5` |

## 6. External verification references used in the accompanying review

The accompanying response cites ITU's official UAE call/FAQ, ITU's official account of the Riyadh winners, the official AI Readiness Framework 2.0, Korean National Law Information Center provisions, and official WHO/OECD material. The source-scope observations above are engineering audit findings; an authorized domain/legal reviewer must confirm operational interpretations before clinical deployment.
